<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517253</url>
  </required_header>
  <id_info>
    <org_study_id>17571</org_study_id>
    <secondary_id>I4V-JE-JAJE</secondary_id>
    <nct_id>NCT04517253</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS</brief_title>
  <official_title>A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult&#xD;
      and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical&#xD;
      neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE),&#xD;
      STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières&#xD;
      Syndrome (AGS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Actual">October 12, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Mean Daily Diary Scores</measure>
    <time_frame>Baseline, up to 32 weeks</time_frame>
    <description>Change from Baseline in Mean Daily Diary Scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decrease in Daily Dose of Corticosteroids</measure>
    <time_frame>Baseline, up to 100 weeks</time_frame>
    <description>Number of participants with decrease in Daily Dose of Corticosteroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Daily Diary Scores</measure>
    <time_frame>Baseline, up to 100 weeks</time_frame>
    <description>Change from Baseline in Mean Daily Diary Scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient's Symptom Specific Daily Diary Scores</measure>
    <time_frame>Baseline, up to 100 weeks</time_frame>
    <description>Change from Baseline in Patient's Symptom Specific Daily Diary Scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Physician's Global Assessment of Disease Activity Scores</measure>
    <time_frame>Baseline, up to 100 weeks</time_frame>
    <description>Change From Baseline in the Physician's Global Assessment of Disease Activity Scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Days Meeting the Criteria of Participant's Mean Daily Diary Score &lt;0.5</measure>
    <time_frame>Pre-treatment period, up to 100 weeks</time_frame>
    <description>Percentage Change of Days Meeting the Criteria of Participant's Mean Daily Diary Score &lt;0.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Growth Velocity</measure>
    <time_frame>Baseline, up to 100 weeks</time_frame>
    <description>Change in Growth Velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Pre-treatment period in Mean Daily Diary Scores</measure>
    <time_frame>Pre-treatment period, up to 100 weeks</time_frame>
    <description>Change from Pre-treatment period in Mean Daily Diary Scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Pre-treatment period in the Physician's Global Assessment of Disease Activity Scores</measure>
    <time_frame>Pre-treatment period, up to 100 weeks</time_frame>
    <description>Change from Pre-treatment period in the Physician's Global Assessment of Disease Activity Scores</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Nakajo-Nishimura Syndrome</condition>
  <condition>Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome</condition>
  <condition>STING-Associated Vasculopathy With Onset in Infancy</condition>
  <condition>Aicardi Goutieres Syndrome</condition>
  <arm_group>
    <arm_group_label>Baricitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally either by tablet or suspension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have systemic signs and symptoms of inflammation as manifested NNS/CANDLE, SAVI, AGS&#xD;
&#xD;
          -  Have been diagnosed with genetic diagnosis&#xD;
&#xD;
          -  Men must agree to use a reliable method of birth control during the study&#xD;
&#xD;
          -  Women not of child-bearing potential or nonbreastfeeding&#xD;
&#xD;
          -  Women must agree to use birth control or remain abstinent during the study and for at&#xD;
             least 12 weeks after stopping treatment&#xD;
&#xD;
          -  NNS/CANDLE and SAVI patients who are ≥17.5 months of age&#xD;
&#xD;
          -  AGS patients who are ≥6 months of age&#xD;
&#xD;
          -  Are ≥ 5kg in body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received immunosuppressive biologic agent/monoclonal antibody/oral JAK&#xD;
             inhibitor/OAT3 inhibitor and cannot discontinue prior to investigational product&#xD;
             initiation. Note: A washout period is required to each drug.&#xD;
&#xD;
          -  Have diagnosis of current active tuberculosis (TB) or, latent TB who did not receive&#xD;
             appropriate treatment.&#xD;
&#xD;
          -  Have had a serious infection within 12 weeks prior to screening.&#xD;
&#xD;
          -  Have a history of lymphoproliferative disease&#xD;
&#xD;
          -  Have any history of venous thromboembolic event (VTE) (deep vein thrombosis&#xD;
             [DVT]/pulmonary embolism [PE]) prior to screening.&#xD;
&#xD;
          -  Have had any major surgery within 8 weeks prior to screening.&#xD;
&#xD;
          -  Have previously been enrolled in any other study investigating baricitinib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima-ken</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Medical Hospital</name>
      <address>
        <city>Bunkyō</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center For Child Health And Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/4deb45sM6OlbQ6MBzCAx6H</url>
    <description>A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nakajo-Nishimura Syndrome</keyword>
  <keyword>CANDLE</keyword>
  <keyword>SAVI</keyword>
  <keyword>AGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

